Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast
Usnoflast, is a “First-in-class” NLRP3 inhibitor to demonstrate proof-of-concept in Phase 2(a) clinical study in ALS patients Usnoflast was well-tolerated ...
Usnoflast, is a “First-in-class” NLRP3 inhibitor to demonstrate proof-of-concept in Phase 2(a) clinical study in ALS patients Usnoflast was well-tolerated ...
NE HEALTH BUREAU AHMEDABAFD, NOV 25 The oral antiviral medication Favipiravir, which prevents the replication phase of the virus life-cycle, ...
NE NEWS SERVICE NEW DELHI, NOV 12 Drug firm Zydus Cadila on Thursday said it has successfully completed a phase ...
NE NEWS SERVICE NEW DELHI, SEPT 16 Drugs Controller General of India (DCGI) Dr V G Somani has gave permission ...
Email:
ne.gowri1964@gmail.com
Phone:
9643255068
© 2021 all right reserved by Navjeevanexpress.com. Consulted by MediaHives.com